Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|

Found 132 Matches

Cidofovir_V12R1_FDA_20150709
Model Files Publication
Table 1 of main text, further discussion in supplemental file. Clarification: the value of intrinsic CL for hepatic elimination (0.41) is for undefined human liver microsomes according to retrograde calculation, with a unit of uL/min/mg. The operating hepatic CLint is driven by S9, which has a value of 0.13, obtained from sensitivity analysis to match HLM value above. This clarification will be informed to the journal.
Search Score: 11
Cetirizine_V14R1_AstraZeneca_20200327
Model Files Publication
Cetirizine for pediatric predictions.
Search Score: 11
Chlorzoxazone_RES_V20R1_Simcyp_20210512
Model Files Publication

The RES-Chlorzoxazone file was primarily developed as an inhibitor of CYP3A4. This document provides: 1. Examples of model performance 2. A summary of the key pharmacokinetic features of Chlorzoxazone considered within the model.

Search Score: 11
Cycloguanil
Model Files Publication

Brand Name(s) include: N/A

Disease: Malaria

Drug Class: Antimalarials

Date Updated: March 2022

Related drugs: Proguanil

The model at-a-glance

  Absorption Model

First-Order

  Volume of Distribution

Full PBPK (Method 2)

  Route of Elimination

Formed by CYP2C19, CYP3A4; unknown clearance mechanism

  Perpetrator DDI
  • CYP2D6 Inhibitor

  Validation

  • Proguanil and cycloguanil files were built using in vitro and clinical (Jeppersen et al., 1997) data
  • 5 clinical studies describing single and multiple dose exposure of cycloguanil were used to verify the PBPK model. 60% of studies were within 2-fold, of which 40% were within 1.5-fold.
  • A clinical DDI study where proguanil was the victim of a CYP2C19-mediated DDI was accurately recovered using the PBPK model.  

  Limitations
  • Prediction of cycloguanil exposure was complicated by not knowing the polymorphism classification of subjects in each study, hence the model performance was deemed acceptable using the criteria of being within 2-fold of observed.
  • Verification needed for perpetrator DDI assessment as literature data is unavailable at this time

  Updates in V19
  • Recalculated fm values using the corrected dose administered in Jeppesen et al., 1997
  • Previous version used paper calculation of total clearance which did not account for the weight of the salt in the 200 mg dose administered
  • Model converted from minimal to full PBPK distribution model
  • Updated in vitro data
  • Updated CYP2D6 IC50

 

Search Score: 11

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|